These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

849 related articles for article (PubMed ID: 33756225)

  • 1. Landscape of SARS-CoV-2 spike protein-interacting cells in human tissues.
    Zheng B; Yuan M; Ma Q; Wang S; Tan Y; Xu Y; Ye J; Gao Y; Sun X; Yang Z; Xu P; Kong L; Wu X; Xu Q
    Int Immunopharmacol; 2021 Jun; 95():107567. PubMed ID: 33756225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diversity of ACE2 and its interaction with SARS-CoV-2 receptor binding domain.
    Low-Gan J; Huang R; Kelley A; Jenkins GW; McGregor D; Smider VV
    Biochem J; 2021 Oct; 478(19):3671-3684. PubMed ID: 34558627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural basis of severe acute respiratory syndrome coronavirus 2 infection.
    Ge J; Zhang S; Zhang L; Wang X
    Curr Opin HIV AIDS; 2021 Jan; 16(1):74-81. PubMed ID: 33186231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular basis for higher affinity of SARS-CoV-2 spike RBD for human ACE2 receptor.
    Delgado JM; Duro N; Rogers DM; Tkatchenko A; Pandit SA; Varma S
    Proteins; 2021 Sep; 89(9):1134-1144. PubMed ID: 33864655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CyDisCo production of functional recombinant SARS-CoV-2 spike receptor binding domain.
    Prahlad J; Struble LR; Lutz WE; Wallin SA; Khurana S; Schnaubelt A; Broadhurst MJ; Bayles KW; Borgstahl GEO
    Protein Sci; 2021 Sep; 30(9):1983-1990. PubMed ID: 34191362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ACE2 glycans preferentially interact with SARS-CoV-2 over SARS-CoV.
    Acharya A; Lynch DL; Pavlova A; Pang YT; Gumbart JC
    Chem Commun (Camb); 2021 Jun; 57(48):5949-5952. PubMed ID: 34019602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential Interactions between Human ACE2 and Spike RBD of SARS-CoV-2 Variants of Concern.
    Kim S; Liu Y; Lei Z; Dicker J; Cao Y; Zhang XF; Im W
    J Chem Theory Comput; 2021 Dec; 17(12):7972-7979. PubMed ID: 34856802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular insights into the binding variance of the SARS-CoV-2 spike with human, cat and dog ACE2 proteins.
    Zang Y; Li X; Zhao Y; Wang H; Hao D; Zhang L; Yang Z; Yuan X; Zhang S
    Phys Chem Chem Phys; 2021 Jun; 23(24):13752-13759. PubMed ID: 34132301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural Basis for Human Receptor Recognition by SARS-CoV-2 Omicron Variant BA.1.
    Geng Q; Shi K; Ye G; Zhang W; Aihara H; Li F
    J Virol; 2022 Apr; 96(8):e0024922. PubMed ID: 35343765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.
    Choudhury A; Mukherjee S
    J Med Virol; 2020 Oct; 92(10):2105-2113. PubMed ID: 32383269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 Spike Protein Destabilizes Microvascular Homeostasis.
    Panigrahi S; Goswami T; Ferrari B; Antonelli CJ; Bazdar DA; Gilmore H; Freeman ML; Lederman MM; Sieg SF
    Microbiol Spectr; 2021 Dec; 9(3):e0073521. PubMed ID: 34935423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Static all-atom energetic mappings of the SARS-Cov-2 spike protein and dynamic stability analysis of "Up" versus "Down" protomer states.
    Peters MH; Bastidas O; Kokron DS; Henze CE
    PLoS One; 2020; 15(11):e0241168. PubMed ID: 33170884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
    David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
    Molecules; 2021 May; 26(11):. PubMed ID: 34072087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2 protein-protein interaction.
    Cao W; Dong C; Kim S; Hou D; Tai W; Du L; Im W; Zhang XF
    Biophys J; 2021 Mar; 120(6):1011-1019. PubMed ID: 33607086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced binding of the N501Y-mutated SARS-CoV-2 spike protein to the human ACE2 receptor: insights from molecular dynamics simulations.
    Luan B; Wang H; Huynh T
    FEBS Lett; 2021 May; 595(10):1454-1461. PubMed ID: 33728680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Withanone from
    Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
    Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies.
    Mercurio I; Tragni V; Busto F; De Grassi A; Pierri CL
    Cell Mol Life Sci; 2021 Feb; 78(4):1501-1522. PubMed ID: 32623480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why Does the Novel Coronavirus Spike Protein Interact so Strongly with the Human ACE2? A Thermodynamic Answer.
    de Andrade J; Gonçalves PFB; Netz PA
    Chembiochem; 2021 Mar; 22(5):865-875. PubMed ID: 33084150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
    Kuba K; Yamaguchi T; Penninger JM
    Front Immunol; 2021; 12():732690. PubMed ID: 35003058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Probing structural basis for enhanced binding of SARS-CoV-2 P.1 variant spike protein with the human ACE2 receptor.
    Lata S; Akif M
    J Cell Biochem; 2022 Jul; 123(7):1207-1221. PubMed ID: 35620980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.